Community oncology plays a central role in the US health care system, offering high-quality care that is both accessible and ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...

As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

Dr. Shune highlights that the growing availability of FDA-approved agents with distinct and complementary mechanisms has ...

Dr. Shune concludes the discussion by focusing on safety, sequencing, and practical considerations for incorporating ...

Overall, this segment establishes a nuanced view of prognosis that avoids binary categorization. Instead, Dr Shaheen frames ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...